Could Aurora Cannabis (TSX:ACB) Have an Aphria (TSX:APH)-Like Earnings Surprise up its Sleeve?

Why Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) could be next in line for a big upside correction.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Just like that, the cannabis industry is hot again, with most pot stocks roaring higher on Friday, despite a rough end to the week with less-than-dovish commentary from the Fed and fresh tariffs slapped on by President Trump to go with threats of retaliation from China — same old, same old.

The wave of optimism that spread across all pot stocks was thanks to Aphria (TSX:APHA)(NYSE:APHA), which clocked in an incredible and surprising earnings beat, sending shares of Aphria soaring over 40% in a single trading session.

At a time when the industry has been plagued by controversy with the CannTrust Holdings fiasco that’s been unfolding in recent weeks, a huge upside surprise was precisely what the doctor ordered for the ailing cannabis industry that seems to be retreating by default.

Add the recent ousting of Canopy Growth ex-CEO Bruce Linton and concerns over the firm’s profitability into the equation, and you’ve got the perfect storm that’d be enough to inspire fear in all but the most contrarian of investors.

As Warren Buffett once said, you need to “be fearful when others are greedy and greedy when others are fearful.” If you took his piece of advice in the crazy world of marijuana, you would have found yourself backing up the truck on the industry that’s in deep bear territory.

While Aphria’s surprise earnings beat was indeed remarkable, I think the highly efficient business model isn’t just unique to the firm itself. Now that we’re nearing the end of year one of legalization, investors expect more than just cash bleed and promises of future growth — they want to see progress on the profitability front. If a nascent industry is to make the jump, some fundamentals are going to need to take hold because in the end, it’ll be the earnings that’ll dictate the trajectory of a stock — not speculation on the occurrence of unforeseen events.

Aphria has set the new high bar to jump, and I think Aurora Cannabis (TSX:ACB)(NYSE:ACB) could be the next company to pole-vault over it. Aurora Cannabis isn’t just focused on growing as much weed as it can over the shortest possible time.

Like Aphria, Aurora is all about increasing crop yields through the use of innovative cultivation techniques, but, more importantly, Aurora has demonstrated an encouraging trajectory of late.

In the first quarter, Aurora beat on earnings and its tripled sales numbers. With a growth strategy poised to profit from the success of international markets, Aurora could see its top-line numbers continue to fly higher as further efficiency improvements are made at the operational level.

Although pundits claim Aurora isn’t the same investment calibre as the likes of a Canopy or Cronos Group, both of which have secured big-league investors, I’d argue that the lack of such a dance partner is an advantage for investors who are looking to jump in today. In a prior piece, I noted that hedge fund manager Nelson Peltz’s strong disapproval for “selling shareholders short” with a potential sell-out to a behemoth of a firm.

“If the cannabis industry continues growing at this triple-digit rate, it’d prove to be an unwise move to take the first big offer that comes rolling in. Instead of buttering up for an acquisition, Battley and company are focused on growth and innovation.” I said in a prior piece.

Sure, Aurora does things differently, but I think it has the potential to leapfrog Canopy and Aphria, as it invests heavily in growth initiatives with consideration for the bottom line as well. Aphria shows that there’s still a lot of gains to be had in the industry. Aurora, I believe, is where the puck could be headed next.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »